Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen

AstraZeneca

Bristol-Myers

Johnson & Johnson

The negotiations with participating drug companies are likely to happen in 2023 and 2024 with the negotiated prices, if any, going into effect in 2026.

Medicare's First Price Negotiation List Targets Expensive Drugs

IQVIA Hlds

Madrigal Pharmaceuticals

This year has not been kind to biotech stocks, as the sector's most popular ETF, the iShares Biotechnology ETF (NASDAQ: IBB ), has fallen about 3% so far in 2023. Investors are probably worried about the impact of higher interest rates and potential reforms by Washington, DC on the sector.

3 Biotech Stocks That Wall Street Analysts Can't Get Enough Of

Reata Pharmaceuticals

It is remarkable that day after day there are pharmaceutical companies working hard, researching and developing high-tech medicines for the improvement of human health and the treatment of severe diseases. These companies not only do a good job of researching and developing cures, but they also have an incredible financial performance.

The 3 Most Promising Pharma Stocks to Own Now

Merck

Eli Lilly's Mounjaro is shaping up to be a long-term driver of earnings growth. The same is true for Merck's Keytruda, a medication for treating certain cancers.

Better Pharma Growth Stock: Eli Lilly vs. Merck

Biogen

Biogen is adding new products to its lineup to reverse its recent revenue decreases. Eli Lilly has a solid portfolio and strong pipeline, and pays a consistent dividend.

Better Buy: Biogen vs. Eli Lilly

INDIANAPOLIS , Aug. 29, 2023  /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the Morgan Stanley 21st Annual Global Healthcare Conference, Sept. 11-12, 2023.

Lilly to Participate in Morgan Stanley 21st Annual Global Healthcare Conference

AbbVie

Novartis

Pfizer

Novo Nordisk

Drugs from AbbVie, Bristol and Merck took slots on the list of drugs subject to price cuts. But the pharmaceutical stocks were unmoved.

Blockbusters From AbbVie, Merck, Lilly Highlight List Of 10 Drugs Subject To Price Cuts

The European Medicines Agency (EMA) said on Monday Eli Lilly & Co's Trulicity, which treats type 2 diabetes in children above 10 years of age, will continue to remain in shortage in Europe through September.

Eli Lilly's diabetes drug to remain in shortage in EU through September

Vertex Pharmaceuticals

Vertex, Eli Lilly, and Novo Nordisk are growing their sales rapidly. All three biotechs have solid portfolios and highly promising pipelines.

3 Top Growth Stocks I'd Buy Right Now Without Hesitation

Expedia

Visa

Savvy investors understand the beauty of having blue-chip stocks. No wonder financial analysts and market professionals recommend having them in your portfolio.

The 3 Blue-Chip Stocks Every Investor Needs to Own Today

Arthur J. Gallagher & Co.

Axon Enterprise

Cintas Corp

W.W. Grainger

O'Reilly Automotive

Progressive

What do investors do when they can get 5% for taking no risk? Find S&P 500 stocks they can make even more on by taking little risk — a tall order only a few can meet.

Warren Buffett Bets His Fortune On One Of 9 'Can't Lose' Stocks

Netflix

NVIDIA

Growth stocks continue to drive both the stock market and investors' portfolios. Game-changing growth stocks to buy that have multi-year catalysts to drive their earnings and share price steadily higher are rare and hard to find.

Want to Get Rich? 3 Game-Changing Growth Stocks to Buy Right Now

Eli Lilly settled another age discrimination lawsuit for an undisclosed amount, just two months after reaching a $2.4 million settlement with the EEOC.

Accused Of Excluding Older Applicants, Eli Lilly Settles Again

A new study by Novo Nordisk points to GLP-1 drugs reducing cardiac risks. It's a relevant finding for Eli Lilly, too, which is already moving forward in clinical trials.

This New Development Is Helping to Send Eli Lilly and Novo Nordisk Stocks Soaring

Airbnb

Eli Lilly could see a couple of key drug approvals from the FDA in the near future. Strong travel demand and an improved platform position Airbnb for continued growth.

Got $5,000? Invest in These 2 Unstoppable Growth Stocks.

The Nasdaq's 15-year period of zero returns highlights the importance of valuation in the long term. Eli Lilly is in an epic bubble, pricing in all growth through 2036 and trading at almost 60X forward earnings. The last time LLY was a 60 PE was the tech bubble. It fell 65% and took 14 years to break even.

Sell Eli Lilly And Buy This Coiled-Spring Dividend Aristocrat Instead

Many different companies are developing therapies for NASH, a liver disease. None has succeeded yet, and some heavy hitters have failed.

Looking for the Next Big Biopharma Stock? These 4 Letters Are 1 Big Clue Where to Find It

Novo Nordisk and Eli Lilly want to use their medicines to treat NASH, a liver disease. Their chances of success are more uncertain than shareholders might wish to see.

Could This 1 Problem Put a Dent in Novo Nordisk and Eli Lilly Stock?

Eli Lilly & Co. LLY, +0.66% on Tuesday reported positive results from a study evaluating its targeted therapy Retevmo versus the current standard initial treatments for patients with advanced or metastatic rearranged during transfection (RET)-mutant medullary thyroid cancer. Retevmo demonstrated a significant and clinically meaningful improvement in progression-free survival, compared with the multikinase inhibitors cabozantinib and vandetanib, Lilly said in a release.

Eli Lilly reports positive results from study of thyroid cancer treatment

Arista Networks

APA Corporation

Constellation Energy Corp

Global Payments

Jacobs Solutions Inc

Regeneron Pharmaceuticals

The S&P 500's plunge in August caught most investors off guard. It's quite a win if you scooped up the handful of gainers in the tough month.

You're An Amazing Stock Picker If You Bought These 8 Stocks This Month

INDIANAPOLIS , Aug. 22, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced topline results from the LIBRETTO-531 study evaluating Retevmo versus physician's choice of the multikinase inhibitors (MKIs) cabozantinib or vandetanib as an initial treatment for patients with advanced or metastatic rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC). The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS).

Lilly's Retevmo® (selpercatinib) Demonstrates Superior Progression-Free Survival Compared to Approved Multikinase Inhibitors in RET-Mutant Medullary Thyroid Cancer

Barring a sharp reversal, the U.S. stock market's five-month winning streak will come to an abrupt end in August. Fortunately, with the S&P 500 having advanced nearly 20% from November to July, this month's downturn may amount to a healthy pullback in a longer uptrend.

Why These 3 Large Caps Are Bucking the August Slump

Large-cap pharmaceuticals have enjoyed buying pressure over the last month, delivering outsized gains to investors. And these three stocks have helped lead the charge.

These 3 Large-Cap Pharma Stocks Have Been Red-Hot

Drug, biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), Novo Nordisk (NVO), Novartis (NVS) and AstraZeneca (AZN) are worth retaining in your portfolio.

5 Large Drug Stocks to Watch as New Drug Approvals & M&A Gain Pace

Eli Lilly has explosive growth potential. Novo Nordisk is worth its premium price tag.

News for Eli Lilly Stock (LLY)